Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence

Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. These effects were not mimicked by nonsulfated CCK, but were blocked by proglumide, a putative CCK antagonist, as well as by antisera raised against sulfated CCK. CCK alone had no effect on locomotion or sterotypy, indicating that this peptide acts primarily as a modulator of DA-mediated behaviors in the mesolimbic pathway. In addition, CCK did not potentiate DA-induced hyperlocomotion or apomorphine-induced stereotypy when injected into the caudate nucleus, where CCK and DA are localized in separate neurons in rats. Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon.

• Publication year

  1985

• Venue

  Journal of Neuroscience

• Publication date

  1985-08-01

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1523/JNEUROSCI.05-08-01972.1985PMID 4040554PMCID PMC6565292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat

  2004cited by this paper
• In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.

  1984cited by this paper
• The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.

  1984cited by this paper
• Behavioral and neurophysiological evidence for a facilatory interaction between co-existing transmitters: cholecystokinin and dopamine.

  1984cited by this paper
• Cholecystokinin receptors: biochemical demonstration and autoradiographical localization in rat brain and pancreas using [3H] cholecystokinin8 as radioligand

  1984cited by this paper
• Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.

  1984cited by this paper
• Effects of cholecystokinin on apomorphine-induced changes of motility in rats.

  1984cited by this paper
• Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats.

  1984cited by this paper
• Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis.

  1984cited by this paper
• Effects of CCK-8 in the nucleus accumbens.

  1984cited by this paper
• Effect of cholecystokinin-octapeptide on dopamine release from slices of cat caudate nucleus

  1984cited by this paper
• Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide.

  1984cited by this paper
• CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors.

  1983cited by this paper
• Multiple dopamine receptors and behavior.

  1983influential reference
• The effects of proglumide on cholecystokinin-, bombesin-, and glucagon-induced satiety in the rat.

  1983cited by this paper
• Dopamine modulates cholecystokinin release in neostriatum

  1983cited by this paper
• Characterization of Cholecystokinin Binding Sites in Rat Cerebral Cortex Using a 125I‐CCK‐8 Probe Resistant to Degradation

  1983cited by this paper
• Influence of cholecystokinin on central monoaminergic pathways.

  1983cited by this paper
• Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons.

  1983cited by this paper
• The origin of cholecystokinin terminals in the basal forebrain of the rat: evidence from immunofluorescence and retrograde tracing.

  1983cited by this paper
• Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

  1983cited by this paper
• CCK nerve terminals in the rat striatal and limbic areas originate partly in the brain stem and partly in telencephalic structures.

  1983cited by this paper
• Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.

  1983cited by this paper
• Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity.

  1983cited by this paper
• Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment.

  1983cited by this paper
• In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.

  1983cited by this paper
• Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the rat.

  1983cited by this paper
• Minimized tolerance to the suppressive effects of CCK8 on operant responding.

  1983cited by this paper
• Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system.

  1983cited by this paper
• Caerulfin and cholecystokinin octapeptide (CCK-8): Sedative and anticonvulsive effects in mice unaffected by the benzodiazepine antagonist Ro 15-1788

  1982cited by this paper
• The role of central and peripheral cholecystokinin in mediating appetitive behaviors.

  1982cited by this paper
• Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8).

  1982cited by this paper
• Effect of 6-hydroxydopamine lesions of the medial forebrain bundle on the distribution of cholecystokinin in rat forebrain.

  1982cited by this paper
• Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation.

  1982cited by this paper
• Minireview. The ascent of cholecystokinin (CCK) - from gut to brain.

  1982cited by this paper
• Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.

  1981cited by this paper
• Suppressive action of cholecystokinin octapeptide on the behavioral effects of L-DOPA in the rat.

  1981cited by this paper
• Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists.

  1981cited by this paper
• Brain-gut peptides and the control of food intake.

  1981cited by this paper
• Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons.

  1981cited by this paper
• Degradation of cholecystokinin-like peptides by a crude rat brain synaptosomal fraction: a study by high pressure liquid chromatography.

  1981cited by this paper
• Distribution of cholecystokinin (CCK) in the hypothalamus and limbic system of the rat

  1981cited by this paper
• Antinociceptive effect of centrally administered caerulein and cholecystokinin octapeptide (CCK-8)☆

  1981cited by this paper
• Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection.

  1980cited by this paper
• Cholecystokinin receptor binding in brain and pancreas: Regulation of pancreatic bindign by cyclic and acyclic guanine nucleotides

  1980cited by this paper
• A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing.

  1980cited by this paper
• Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides.

  1980cited by this paper
• Evidence for coexistence of dopamine and CCK in meso-limbic neurones

  1980cited by this paper
• Demonstration of a putative receptor site for cholecystokinin in rat brain

  1980cited by this paper
• Cholecystokinin receptors in the brain: characterization and distribution.

  1980cited by this paper
• Effects of cholecystokinin-like peptides on rearing activity and hexobarbital-induced sleep.

  1980cited by this paper
• Investigation of cholecystokinin-octapeptide splitting enzyme in dog kidney.

  1979cited by this paper
• Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate‐putamen

  1977cited by this paper
• The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system.

  1975influential reference
• Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens

  1973cited by this paper
• Injection of solutions into cerebral tissue: Relation between volume and diffusion

  1966cited by this paper

• Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment.

  2025cites this paper
• Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease.

  2024cites this paper
• Cholecystokinin exerts a major control on corticostriatal synapse and motor behavior

  2022cites this paper
• Psychiatric Comorbidities in Parkinson's Disease Seen through the Prism of Genomics and Epigenetics.

  2021cites this paper
• Neural network with multiple connection weights

  2020cites this paper
• Psychosis in Parkinson's disease: From the soft signs to the hard science.

  2017cites this paper
• Genetic substrates of psychosis in patients with Parkinson's disease: A critical review.

  2016cites this paper
• The role of cholecystokinin in the induction of aggressive behavior: a focus on the available experimental data (review).

  2013cites this paper
• Structure-activity relationships of CCK26-33-related analogues modified in position 33

  2009cites this paper
• Effekte der systemischen Cholecystokiningabe bei C57BL/6-Mäusen und Einfluss einer chronischen Vitamin D- und /oder Paroxetinbehandlung auf das Verhalten und die HPA-Ahcse bei C57BL/6- und DBA/2-Mäusen

  2009cites this paper
• Neuroregulation of nonexercise activity thermogenesis and obesity resistance.

  2008cites this paper
• Engrailed-2 regulates genes related to vesicle formation and transport in cerebellar Purkinje cells.

  2008cites this paper
• The myth of panic spontaneity: Consideration of behavioral and neurochemical sensitization.

  2007cites this paper
• Neuropeptidergic Mediators of Spontaneous Physical Activity and Non-Exercise Activity Thermogenesis

  2007cites this paper
• Neuroendocrine Control of Peripheral Metabolic Function

  2007cites this paper
• Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse

  2005cites this paper
• Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain

  2004cites this paper
• CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats

  2004cites this paper
• Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry

  2004cites this paper
• Possible association of a cholecystokinin promoter variant to schizophrenia.

  2002cites this paper
• Cholecystokinin modulation of apomorphine- or amphetamine-induced stereotypy in rats: opposite effects.

  2001cites this paper
• Sexual Behavior Induction of c-Fos in the Nucleus Accumbens and Amphetamine-Stimulated Locomotor Activity Are Sensitized by Previous Sexual Experience in Female Syrian Hamsters

  2001influential citation
• Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors.

  2000cites this paper
• Self-administration of intravenous amphetamine: effect of nucleus accumbens CCKB receptor activation on fixed-ratio responding

  1999cites this paper
• Cognitive enhancing effects in young and old rats of pBC264, a selective CCKB receptor agonist

  1999cites this paper
• Cholecystokinergic innervation of nucleus accumbens subregions.

  1998cites this paper
• Cholecystokinin as a target for neuropsychiatric drugs.

  1998cites this paper
• Cholecystokinin, β-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls

  1998cites this paper
• Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls.

  1998cites this paper
• Relationship between SCL-90, Maudsley Personality Inventory and CCK4-induced intracellular calcium response in T cells.

  1998cites this paper
• Amphetamine‐induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens

  1998cites this paper
• The CCK‐B Agonist, BC264, Increases Dopamine in the Nucleus Accumbens and Facilitates Motivation and Attention After lntraperitoneal Injection in Rats

  1997cites this paper
• Cholecystokinin and Psychiatric Disorders

  1997cites this paper
• Modulation of apomorphine-induced stereotyped behavior by cholecystokinin.

  1997cites this paper
• Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine and dizocilpine maleate.

  1997cites this paper
• The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?

  1997cites this paper
• Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.

  1996cites this paper
• Individual differences in the feeding response to CCKB antagonists: role of the nucleus accumbens.

  1996cites this paper
• Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat.

  1996cites this paper
• Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain

  1996cites this paper
• Novel CCK-B receptor agonists: diketopiperazine analogues derived for CCK4 bioactive conformation.

  1996cites this paper
• Two faces of cholecystokinin: anxiety and schizophrenia

  1996cites this paper
• Cholecystokinin and Anxiety: From Neuron to Behavior

  1995cites this paper
• Cholecystokinin modulates mesolimbic dopaminergic influences on male rat copulatory behavior.

  1995cites this paper
• CCK, Addiction and Anxiety

  1995cites this paper
• Interactions between Cholecystokinin and Other Neurotransmitter Systems

  1995cites this paper
• The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats

  1995cites this paper
• The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol.

  1994cites this paper
• Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding.

  1994cites this paper
• Biological actions of cholecystokinin.

  1994cites this paper
• Neurobiology of cholecystokinin.

  1994cites this paper
• Dopamine receptors: molecular biology, biochemistry and behavioural aspects.

  1994cites this paper
• CCK, Schizophrenia, and Anxiety

  1994cites this paper
• CCK antagonists: pharmacology and therapeutic interest.

  1994cites this paper
• Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors.

  1994cites this paper
• Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion.

  1994cites this paper
• Cholecystokinin Modulates Dopamine‐Mediated Behaviors

  1994cites this paper
• Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA.

  1993cites this paper
• CCK peptides and mRNA in the human brain.

  1993cites this paper
• Total synthesis, purification, and characterization of human [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK20–58, [Tyr52, Nle32,53,56,Nal55]-CCK-58, and [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK-58

  1993cites this paper
• Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat.

  1993cites this paper
• PREDICTION OF ANTIPSYCHOTIC ACTIVITY

  1993cites this paper
• Cholecystokinin-dopamine interactions within the nucleus accumbens in the control over behaviour by conditioned reinforcement.

  1993cites this paper
• Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders.

  1993cites this paper
• Decreased tyrosine hydroxylase mRNA but not cholecystokinin mRNA in the pars compacta of the substantia nigra and ventral tegmental area of aged rats.

  1993cites this paper
• The potential role of cholecystokinin in schizophrenia: review and update

  1993cites this paper
• Inhibition of A9 and A10 dopamine cells by the cholecystokinin‐B antagonist LY262691: Mediation through feedback pathways from forebrain sites

  1993cites this paper
• Cholecystokinin-dependent regulation of host dopamine inputs to striatal grafts.

  1993cites this paper
• Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.

  1992cites this paper
• Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.

  1992cites this paper
• Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists.

  1992cites this paper
• In Situ Hybridization and Immunohistochemical Methods in Study of Regulatory Molecules

  1992cites this paper
• Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway

  1992influential citation
• Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain.

  1992cites this paper
• Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats.

  1992cites this paper
• The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats.

  1992cites this paper
• Effects of diurnal phase and pimozide on cholecystokinin-elicited hypoactivity in the hamster.

  1992cites this paper
• [The structural organization and neurochemical mechanisms of the participation of the nucleus accumbens in the interaction of the limbic and motor systems and in the regulation of motor behavior].

  1992cites this paper
• Cortico‐Subcortical Interactions in Behavioral Sensitization: Differential Effects of Daily Nicotine and Morphine

  1992cites this paper
• Autoradiographic Localization of Cholecystokinin A and B Receptors in Rat Brain Using [125I]D‐Tyr25 (NIe28,31)‐CCK 25‐33S

  1992cites this paper
• Placebo‐Controlled, Double‐Blind Study of the Effects of Proglumide in the Treatment of Schizophrenia

  1992cites this paper
• Polyamines inhibit N-methyl-D-aspartate antagonist-induced darting behavior in the rat prefrontal cortex.

  1992cites this paper
• Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens.

  1991cites this paper
• Cholecystokinin-dopamine intearctions

  1991cites this paper
• The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons.

  1991cites this paper
• [The neurotoxicity of benzodiazepines].

  1991cites this paper
• Involvement of Dopamine in Inhibition of Food Intake by Cholecystokinin Octapeptide in Male Rats

  1991cites this paper
• CCK-8 modulates D2 receptor agonist-induced hypermotility in the nucleus accumbens.

  1991cites this paper
• Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats.

  1991cites this paper
• Cholecystokinin-dopamine interactions.

  1991cites this paper
• Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.

  1991cites this paper
• Neuromodulatory actions of dopamine and cholecystokinin in the ventral striatum.

  1991cites this paper
• Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.

  1991cites this paper
• Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin.

  1991cites this paper
• Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.

  1991cites this paper
• Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens.

  1990cites this paper
• Behavioral characterization of intracranial self-stimulation from mesolimbic, mesocortical, nigrostriatal, hypothalamic and extra-hypothalamic sites in the non-inbred CD-1 mouse strain.

  1990cites this paper
• Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat

  1990cites this paper
• Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration

  1990cites this paper
• Involvement of Cholecystokinin in Food Intake: I. Concentrations of Cholecystokinin‐Like Immunoreactivity in the Cerebrospinal Fluid of Male Rats

  1990cites this paper